Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 115, Issue 2, Pages 272-278Publisher
WILEY
DOI: 10.1046/j.1365-2141.2001.03169.x
Keywords
Hodgkin's Disease; [F-18]-FDG-PET; first-line treatment; residual disease; prognostic value
Categories
Ask authors/readers for more resources
To assess the ability of restaging positron emission tomography (PET) scanning to predict clinical outcome after first-line treatment in patients with Hodgkin's disease, we included 60 patients with histologically proven HD. who underwent whole-body [F-18]-fluorodeoxygenase ([F-18]-FDG)-PET studies after first-line treatment and with a follow-up of at least 1 year. Persistence or absence of residual disease on PET was related to progression-free survival (PFS) using Kaplan-Meier survival analysis. After treatment, 55 patients showed a normal [F-18]-FDG-PET scan; 50 of 55 remained in complete remission (CR), with a median follow-up of 955 d. Only five patients relapsed (median PFS, 296 d). During follow-up in all five patients, [F-18]-FDG-PET was the first tool that became positive for relapse. Persistent abnormal [F-18]-FDG uptake was seen in only five patients: all of them relapsed (median PFS, 296 d). In four of five patients, only PET predicted persistent disease. All relapses were proven histologically. Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [F-18]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available